These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 28988716)

  • 21. Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes.
    Kinberger GA; Prakash TP; Yu J; Vasquez G; Low A; Chappell A; Schmidt K; Murray HM; Gaus H; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3690-3. PubMed ID: 27268307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor.
    Schmidt K; Prakash TP; Donner AJ; Kinberger GA; Gaus HJ; Low A; Østergaard ME; Bell M; Swayze EE; Seth PP
    Nucleic Acids Res; 2017 Mar; 45(5):2294-2306. PubMed ID: 28158620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serial incorporation of a monovalent GalNAc phosphoramidite unit into hepatocyte-targeting antisense oligonucleotides.
    Yamamoto T; Sawamura M; Wada F; Harada-Shiba M; Obika S
    Bioorg Med Chem; 2016 Jan; 24(1):26-32. PubMed ID: 26678173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes.
    Tanowitz M; Hettrick L; Revenko A; Kinberger GA; Prakash TP; Seth PP
    Nucleic Acids Res; 2017 Dec; 45(21):12388-12400. PubMed ID: 29069408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ligands of the asialoglycoprotein receptor for targeted gene delivery, part 1: Synthesis of and binding studies with biotinylated cluster glycosides containing N-acetylgalactosamine.
    Westerlind U; Westman J; Törnquist E; Smith CI; Oscarson S; Lahmann M; Norberg T
    Glycoconj J; 2004; 21(5):227-41. PubMed ID: 15486455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of improved GalNAc conjugation in development of cost-effective siRNA therapies targeting cardiovascular diseases.
    Li Q; Yin K; Ma HP; Liu HH; Li S; Luo X; Hu R; Zhang WW; Lv ZS; Niu XL; Gu MH; Li CL; Liu YS; Liu YJ; Li HB; Li N; Li C; Gu WW; Li JJ
    Mol Ther; 2024 Mar; 32(3):637-645. PubMed ID: 38204163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo.
    Rensen PC; Sliedregt LA; Ferns M; Kieviet E; van Rossenberg SM; van Leeuwen SH; van Berkel TJ; Biessen EA
    J Biol Chem; 2001 Oct; 276(40):37577-84. PubMed ID: 11479285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of modular conjugation strategy for
    Yamamoto T; Sawamura M; Terada C; Kashiwada K; Wada F; Yamayoshi A; Obika S; Harada-Shiba M
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):109-118. PubMed ID: 31617782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis of Monovalent N-Acetylgalactosamine Phosphoramidite for Liver-Targeting Oligonucleotides.
    Yamamoto T; Terada C; Kashiwada K; Yamayoshi A; Harada-Shiba M; Obika S
    Curr Protoc Nucleic Acid Chem; 2019 Sep; 78(1):e99. PubMed ID: 31529782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Engineering a biomimetic system for hepatocyte-specific RNAi treatment of non-alcoholic fatty liver disease.
    He X; Chang Z; Chen F; Zhang W; Sun M; Shi T; Liu J; Chen P; Zhang K; Guan S; Zhao Z; Li M; Dong WF; Shao D; Yang C
    Acta Biomater; 2024 Jan; 174():281-296. PubMed ID: 37951519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models.
    Kim Y; Jo M; Schmidt J; Luo X; Prakash TP; Zhou T; Klein S; Xiao X; Post N; Yin Z; MacLeod AR
    Mol Ther; 2019 Sep; 27(9):1547-1557. PubMed ID: 31303442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of gal/GalNAc regioisomerism in galactosylated liposomes on asialoglycoprotein receptor-mediated hepatocyte-selective targeting
    Nie H; Qiu B; Yang QX; Zhao Y; Liu XM; Zhang YT; Liao FL; Zhang SY
    J Liposome Res; 2021 Mar; 31(1):79-89. PubMed ID: 31691619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo.
    Wong SC; Klein JJ; Hamilton HL; Chu Q; Frey CL; Trubetskoy VS; Hegge J; Wakefield D; Rozema DB; Lewis DL
    Nucleic Acid Ther; 2012 Dec; 22(6):380-90. PubMed ID: 23181701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficient Liver Targeting by Polyvalent Display of a Compact Ligand for the Asialoglycoprotein Receptor.
    Sanhueza CA; Baksh MM; Thuma B; Roy MD; Dutta S; Préville C; Chrunyk BA; Beaumont K; Dullea R; Ammirati M; Liu S; Gebhard D; Finley JE; Salatto CT; King-Ahmad A; Stock I; Atkinson K; Reidich B; Lin W; Kumar R; Tu M; Menhaji-Klotz E; Price DA; Liras S; Finn MG; Mascitti V
    J Am Chem Soc; 2017 Mar; 139(9):3528-3536. PubMed ID: 28230359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triplex Hybridization of siRNA with Bifacial Glycopolymer Nucleic Acid Enables Hepatocyte-Targeted Silencing.
    Xia X; Zhou Z; DeSantis C; Rossi JJ; Bong D
    ACS Chem Biol; 2019 Jun; 14(6):1310-1318. PubMed ID: 31141333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Capacity limits of asialoglycoprotein receptor-mediated liver targeting.
    Bon C; Hofer T; Bousquet-Mélou A; Davies MR; Krippendorff BF
    MAbs; 2017; 9(8):1360-1369. PubMed ID: 28876162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physiological roles of asialoglycoprotein receptors (ASGPRs) variants and recent advances in hepatic-targeted delivery of therapeutic molecules via ASGPRs.
    Hu J; Liu J; Yang D; Lu M; Yin J
    Protein Pept Lett; 2014; 21(10):1025-30. PubMed ID: 24975671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Asialoglycoprotein Receptor-Mediated Gene Delivery to Hepatocytes Using Galactosylated Polymers.
    Thapa B; Kumar P; Zeng H; Narain R
    Biomacromolecules; 2015 Sep; 16(9):3008-20. PubMed ID: 26258607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal of siRNA-mediated gene silencing in vivo.
    Zlatev I; Castoreno A; Brown CR; Qin J; Waldron S; Schlegel MK; Degaonkar R; Shulga-Morskaya S; Xu H; Gupta S; Matsuda S; Akinc A; Rajeev KG; Manoharan M; Maier MA; Jadhav V
    Nat Biotechnol; 2018 Jul; 36(6):509-511. PubMed ID: 29786096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholesterol-GalNAc Dual Conjugation Strategy for Reducing Renal Distribution of Antisense Oligonucleotides.
    Wada F; Yamamoto T; Ueda T; Sawamura M; Wada S; Harada-Shiba M; Obika S
    Nucleic Acid Ther; 2018 Feb; 28(1):50-57. PubMed ID: 29360004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.